Trial Profile
A phase 1 clinical trial for the safety and pharmacokinetic assessment of the adalimumab biosimilar (CT-P17)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- 20 Aug 2018 New trial record
- 07 Aug 2018 According to a Celltrion media release, is set to launch phase 1 clinical trials for the safety and pharmacokinetic assessment of the adalimumab biosimilar in the UK.